OraSure Technologies Completes Asset Acquisition/Disposition

TL;DR

OraSure just closed a deal on its assets, filing an 8-K.

AI Summary

On December 19, 2024, OraSure Technologies, Inc. entered into a material definitive agreement related to the completion of an acquisition or disposition of assets. The filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates a significant corporate action for OraSure Technologies, Inc., likely involving the acquisition or sale of assets, which could impact its business operations and financial structure.

Risk Assessment

Risk Level: medium — The filing pertains to a material definitive agreement and completion of an acquisition or disposition of assets, which inherently carries business and financial risks.

Key Players & Entities

• OraSure Technologies, Inc. (company) — Registrant
• December 19, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-16537 (filing_id) — Commission File Number
• 36-4370966 (tax_id) — I.R.S. Employer Identification No.
• 220 East First Street (address) — Principal Executive Offices
• Bethlehem (city) — Principal Executive Offices
• Pennsylvania (state) — Principal Executive Offices
• 18015-1360 (zip_code) — Principal Executive Offices
• 610 - 882-1820 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.000001 — ange on which registered Common Stock, $0.000001 par value per share OSUR The Nasdaq
• $5 million — er Agreement: (i) an upfront payment of $5 million (such payment, the "Initial Merger Cons
• $20 m — stone payments of up to an aggregate of $20 million, each conditioned upon the achiev

Filing Documents

• d884076d8k.htm (8-K) — 39KB
• 0001193125-24-285106.txt ( ) — 159KB
• osur-20241219.xsd (EX-101.SCH) — 3KB
• osur-20241219_lab.xml (EX-101.LAB) — 17KB
• osur-20241219_pre.xml (EX-101.PRE) — 11KB
• d884076d8k_htm.xml (XML) — 3KB

Forward Looking Statements

Forward Looking Statements This Current Report contains certain "forward-looking statements" within the meaning of the Federal securities laws, including with respect to products, product development and manufacturing activities, the Company's acquisition of Sherlock, revenue growth, cash flow, increasing margins and other matters. Words such as "expects," "estimates," "forecasts," "intends," "plans," "projects," "could," "may," "should," "will" or other similar words and expressions are intended to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: the Company's ability to integrate Sherlock's business and achieve the intended benefits of the acquisition on the timeline expected or at all; Sherlock's ability to seek and obtain regulatory approval for products in development; the Company's ability to satisfy customer demand; ability to reduce the Company's spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of the Company's business restructuring, including from insourcing third party manufacturing and exiting microbiome services; ability to market and sell products, whether through the Company's internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company's products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indi

Financial Statements and Exhibits

Financial Statements and Exhibits. (a) Financial Statements of the Business Acquired. Financial statements, to the extent required by this Item 9.01, will be filed by amendment to this Current Report on Form 8-K within seventy-one (71) calendar days from the date that this Current Report on Form 8-K is required to be filed. (b) Pro Forma Financial Information. Pro forma financial information, to the extent required by this Item 9.01, will be filed by amendment to this Current Report on Form 8-K within seventy-one (71) calendar days from the date that this Current Report on Form 8-K is required to be filed. 4 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORASURE TECHNOLOGIES, INC. Date: December 26, 2024 By: /s/ Carrie Eglinton Manner Carrie Eglinton Manner President and Chief Executive Officer 5

View Full Filing

View this 8-K filing on SEC EDGAR